Background Crohn's disease and ulcerative colitis are the two major forms of infl ammatory bowel disease; treatment strategies have historically been determined by this binary categorisation. Genetic studies have identifi ed 163 susceptibility loci for infl ammatory bowel disease, mostly shared between Crohn's disease and ulcerative colitis. We undertook the largest genotype association study, to date, in widely used clinical subphenotypes of infl ammatory bowel disease with the goal of further understanding the biological relations between diseases.
Introduction
Crohn's disease and ulcerative colitis, the two major forms of infl ammatory bowel disease, aff ect about one in 200 people in developed countries, with a rising incidence and prevalence in developing countries. 1 Many patients with infl ammatory bowel disease have a lifetime of debilitating physical symptoms (eg, urgent diarrhoea, rectal bleeding, vomiting, anorexia, and lethargy), which frequently lead to poor psychosocial wellbeing with wide ranging consequences for academic attainment, employment, relationships, and sexual health. 2 Furthermore, the fi nancial costs of infl ammatory bowel disease are substantial and are estimated at more than US$2·2 billion per year in the USA alone. 3 Infl ammatory bowel disease is characterised by an exaggerated mucosal immune response to luminal gut contents in genetically susceptible individuals. 4 In Crohn's disease, infl ammation can occur in any part of the gastrointestinal tract, whereas ulcerative colitis is typically confi ned to the colon. The universally adopted Montreal classifi cation distinguishes clinical subphenotypes in Crohn's disease by disease location and behaviour, and age of onset, and in ulcerative colitis by disease extent and age of onset. [5] [6] [7] [8] [9] [10] [11] Molecular studies have suggested that ileal and colonic Crohn's disease are distinct entities because variants in NOD2 are associated with small bowel disease and HLA alleles with colonic disease. [12] [13] [14] [15] [16] [17] [18] [19] However, current recommendations do not advocate the use of these established markers in making treatment decisions, nor for choosing patients for clinical trials. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The natural history and clinical course of infl ammatory bowel disease is very heterogeneous: up to 20% of patients with ulcerative colitis need colectomy for medically refractory disease, and more than 50% of patients with Crohn's disease need surgery within 10 years of diagnosis; 30 however, up to 50% of patients with ulcerative colitis and 30% with Crohn's disease will have a fairly indolent disease course without the need for immunosuppression or surgery. 31, 32 Infl ammatory bowel disease has been at the vanguard of progress in understanding the genetic framework of complex diseases, with 163 susceptibility loci identifi ed so far. 33 Most infl ammatory bowel disease loci confer risk of both ulcerative colitis and Crohn's disease, but typically show distinct eff ect sizes in the two disorders. These fi ndings suggest that genetic variation might defi ne molecular subtypes independent of traditional and clinically defi ned diagnostic entities, allowing new insights into the molecular basis of these subphenotypes.
Our international study of around 30 000 patients with infl ammatory bowel disease genotyped by microarray is the largest genotype-subphenotype study in the disease done so far. We have used genetic risk scores to study genetic heterogeneity underpinning the natural history of infl ammatory bowel disease. This analysis rejects the current binary classifi cation of Crohn's disease and ulcerative colitis as distinct and homogeneous clinical entities in favour of a continuum of illness better fi t by a three-category model (ie, ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis). We show that these risk scores have clinical potential (although they are currently only weak predictors), and believe they might have widespread applicability in other diseases.
Methods

Study design and patients
We acquired phenotype data for 34 819 patients, including 19 713 with Crohn's disease and 14 683 with ulcerative colitis. The cohort included all patients in diff erent centres over the years who had infl ammatory bowel disease as per Lennard-Jones' criteria. 34 All inclusion criteria are included in appendix A. After quality control (appendix A), the primary analysis included 29 838 patients (16 902 with Crohn's disease, 12 597 with ulcerative colitis, 255 with indeterminate colitis, and 84 missing an exact diagnosis). This study includes patients from population-based registries, and secondary and tertiary-referral centres at 49 sites in 16 countries in Europe, North America, and Australasia, most of which have been previously described (appendix B). 33 Confi rmation of diagnosis of infl ammatory bowel disease and assignment of clinical subphenotypes were done by clinicians specialising in infl ammatory bowel disease or trained phenotypers through case note reviews of clinical, radiological, histopathological, and endoscopic reports, and classifi ed per the Montreal classifi cation criteria (see appendix A for details). 8, 9 For behaviour and surgery in Crohn's disease, and colectomy in ulcerative colitis, Kaplan-Meier
Research in context
Evidence before this study We searched PubMed for genotype-phenotype association studies in infl ammatory bowel disease, published between Jan 1, 1996, and Oct 17, 2014, with the search terms "infl ammatory bowel disease" AND "genotype phenotype" AND "genetic association" AND ("disease course" or "disease extent" or "location behaviour"). We found 31 studies with sample sizes of 66 to 2804 patients, and studying between one and 163 genetic variants. Most of these studies implicated NOD2 and HLA in subphenotypes of infl ammatory bowel disease. Many studies, especially the early ones, studied only NOD2 and HLA, and none included genetic variants not previously implicated in risk for infl ammatory bowel disease.
Added value of this study
This study is the largest genotype-phenotype study of infl ammatory bowel disease by at least a factor of ten, and is among the largest studies of genetic determinants of clinical subphenotypes of any complex disease. We have refi ned the known associations (for instance, the eff ect of NOD2 on disease behaviour is entirely driven by its association with disease location) and discovered one new associated locus (3p21/MST1 with age at diagnosis) . We have explored the genetic relations between subtypes of infl ammatory bowel disease with genetic risk scores for the fi rst time, and have shown that ileal and colonic Crohn's disease are at least as genetically distinct from each other as they are from ulcerative colitis.
Implications of all the available evidence
Established genetic factors can only explain a small fraction of the variability in subphenotype of infl ammatory bowel disease, but genetic risk scores that capture all this information could be used to identify misdiagnosed patients. Future translational and clinical research should move away from a binary classifi cation of infl ammatory bowel disease into ulcerative colitis and Crohn's disease, instead considering ileal and colonic Crohn's disease as separate disease entities.
survival curves, stratifi ed by location of Crohn's disease and extent of ulcerative colitis, were drawn to estimate time to fi rst event (see appendix A for details).
The ethical boards of each separate recruiting centre approved the study. All patients included in this study gave written informed consent.
Procedures
All cases were genotyped with the Immunochip array (Illumina, San Diego, CA, USA; appendix B) as previously described. 33 Briefl y, the Immunochip is a 195 806-polymorphism genotyping platform comprising variants identifi ed from association studies of immune-related disorders including Crohn's disease and ulcerative colitis. Extensive quality control was performed on the dataset (appendix A), leaving 29 838 cases and 156 154 markers available for analyses. Variants in the MHC, including 23 HLA alleles that have been implicated in infl ammatory bowel disease, were imputed as described in appendix A. 35 All association tests were done on all genotyped variants, conditional on the fi rst fi ve principal components to account for population structure. Age of onset was analysed for Crohn's disease and ulcerative colitis separately and then meta-analysed; time to surgery was analysed with parametric survival-time regression models; and upper gastrointestinal involvement and perianal disease were analysed with binary logistic regression (see appendix A). For multicategory phenotypes (disease location, behaviour, and extent) we used model selection to pick the most appropriate genetic model for the phenotype (appendix A). The model selection indicated a multinomial model for Crohn's disease location (ie, three unordered categories), an ordinal logistic model for Crohn's disease behav iour (three ordered categories, B3 penetrating>B2 stricturing>B1 infl ammatory), and a binary model for disease extent of ulcerative colitis (two categories: E3 extensive disease vs E2 left-sided disease and E1 proctitis). To distinguish direct associations from indirect (ie, driven by an association with a correlated phenotype), we also adjusted all regression models for the other phenotypes (age of onset, location, and behaviour for Crohn's disease; age of onset and disease extent for ulcerative colitis). Genome-wide signifi cance (p<5 × 10 -⁰⁸) was required for individual single nucleotide poly morphisms (SNPs) and HLA types.
All signals that showed suggestive association (p<1 × 10 -⁵) with any of the disease subphenotypes were assessed in an independent cohort genotyped on a range of diff erent genome-wide association study (GWAS) chips. These samples have also undergone rigorous quality control and imputation. 33 Phenotype data for an additional and independent 2453 patients with Crohn's disease and 3729 patients with ulcerative colitis were available for these analyses. See appendix A for additional information about the replication cohort.
To learn about the relative phenotypic variance explained by diff erent risk factors in adult infl ammatory bowel disease, we fi tted a model to predict Crohn's disease location that included both demographic predictors (smoking status, age at diagnosis, and year) and genetic predictors (SNPs at NOD2, MST1, and the HLA cluster as well as the genetic risk score). Variance explained on the logit scale by each predictor was calculated with the McKelvey-Zavoina pseudo R². Centres with a high proportion (>60%) of missing data for smoking status were removed. To reduce the eff ect of changes in clinical practice and smoking rates, only patients born between 1955 and 1985 were included.
In addition to looking at single SNPs, we also combined information from 193 SNPs and 23 HLA types previously associated with infl ammatory bowel disease to generate genetic risk scores (appendix A), which provide better predictive accuracy than individual SNPs. To assess classifi cation accuracy, we re-ran the risk score analyses with a cross-validation strategy, in which models were fi tted in non-UK origin samples and assessed by how well they classifi ed UK samples.
To assess if the risk score can be used to identify misclassifi ed patients, we selected 97 outlier patients that fell in the extreme tail of the scores for the opposite phenotype (log Crohn's disease versus ulcerative colitis [CD vs UC] score ≤-2 for Crohn's disease outliers and log CD vs UC score ≥2 for ulcerative colitis outliers), as well as 95 randomly selected cases with non-outlier scores matched by recruitment centre. Clinicians from each centre were then asked to re-phenotype both outlier and non-outlier patients in a masked fashion. The CD versus UC risk score was chosen for this experiment because it had the strongest association with Crohn's disease location and behaviour.
Statistical analysis
The median eff ect size of known infl ammatory bowel disease risk variants 33 was about OR 1·1, with a median minor allele frequency of roughly 30%. The sample size of our study gave us high power to detect an eff ect of equivalent magnitude of Crohn's disease location (power of 67% for ileal vs non-ileal disease), Crohn's disease behaviour (94% for complicated vs non-complicated disease) and ulcerative colitis disease extent (84% for extensive vs nonextensive disease) at genome-wide signifi cance. Binary and linear genotype-phenotype analyses were done with PLINK version 1.07, 36 and multinomial and ordinal regression with a custom program, Trinculo version 0.4 (appendix A). Survival analysis and risk prediction were done with R-2.15.1 using the packages "survival" and "Mangrove", 37 respectively. Data handling and plotting was done with R.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the See Online for appendix data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Our primary analyses were done on matched genotype and phenotype data from 29 838 patients of European ancestry (appendix A) with infl ammatory bowel disease (16 902 with Crohn's disease, 12 597 with ulcerative colitis; table 1) with a total of 217 195 patient-years of follow-up (median per patient: 11 years for Crohn's disease and 10 years for ulcerative colitis). Demographic features of the study population agreed with previously published results: patients with Crohn's disease were more likely to be younger at diagnosis, female, smokers, and have aff ected family members than were patients with ulcerative colitis (table 1). Extensive disease was more common in those diagnosed at a younger age in both Crohn's disease and ulcerative colitis, whereas disease behaviour was relatively unaff ected by age at diagnosis (appendix A). Reaffi rming the progressive nature of Crohn's disease, the proportion of patients with stricturing (B2) or penetrating (B3) disease increased from less than 30% (n/N) at diagnosis to 43% (n/N) at 5 years, 56% (n/N) at 10 years, and 74% (n/N) at 30 years (fi gure 1, which shows the progression in B1, B2, and B3 disease individually [smoothed estimates over intervals]). By contrast, disease location showed little variation during the same period (fi gure 1). With the exception of the population-based cohorts from Scandinavia, survival analyses of time to development of complicated disease (B2, B3) or fi rst surgery in Crohn's disease were highly consistent across the diff erent countries of origin despite diff erent health-care systems and methods of sampling (appendix A). In Crohn's disease, time from diagnosis to progression (complicated disease or surgical inter vention) was signifi cantly shorter in purely ileal (L1) compared with ileocolonic (L3) or colonic (L2) disease (p<10¯¹⁰⁰; fi gure 1; appendix A). Overall, 7257 (52%) of 13 862 patients with Crohn's disease had undergone surgery by the time of last follow-up. In ulcerative colitis, in which the overall rate of colectomy was 22% 10 years after diagnosis, time to surgery was shorter in patients with extensive disease (E3) than in those with left-sided disease (E2) or proctitis (E1; p=8 × 10¯⁸⁴; fi gure 1).
We tested genetic variants for association with age at diagnosis and time to surgery in all patients with infl ammatory bowel disease; disease location and behaviour in Crohn's disease; and disease extent in ulcerative colitis (table 2 and table 3) . Across all analyses, three loci achieved genome-wide signifi cance (p<5 × 10 -⁸): 3p21 (MST1), NOD2, and the MHC. No additional signals were noted after replication of suggestive loci (p<1 × 10 -⁵) in an independent GWAS cohort (appendix B). Although NOD2 was strongly associated with Crohn's disease location, behaviour, and age at diagnosis, adjustment for the other phenotypes showed that the association of NOD2 with behaviour was driven almost entirely by its phenotypic correlation with location and age at diagnosis (fi gure 2).
We noted complex and correlated HLA signals for susceptibility to infl ammatory bowel disease overall and age at onset, as well as Crohn's disease location and behaviour, extent of ulcerative colitis, and surgery (fi gure 2; appendix A; appendix B). In-depth analysis of the MHC region including classical HLA alleles showed that the strongest signal for disease location was a colonic association with HLA-DRB1*01:03 (p=1·47 × 10 -²³; ileal vs colonic odds ratio [OR] 0·32, 95% CI 0·29-0·41; ileocolonic vs colonic OR 0·47, 0·39-0·57), which is also the strongest shared risk allele for Crohn's disease and ulcerative colitis, 35 followed by HLA-DRB1*07:01 (fi gure 2; appendix A). rs77005575 was independently associated with Crohn's disease behaviour (p=1·56 × 10 -⁰⁹; fi gure 2; appendix A). Notably, alleles associated with susceptibility to ulcerative colitis were better predictors of colonic disease location in Crohn's disease than alleles associated with susceptibility to Crohn's disease (appendix A). The top signal for extent of ulcerative colitis was rs3115674 (p=5·11 × 10 -¹⁷; OR 0·70, 0·64-0·76; appendix A), which correlates with HLA-B*08 (R²=0·66), found mostly on the ancestral 8.1 HLA haplotype. HLA-DRB1*13:01 was the top signal for age at diagnosis of ulcerative colitis (3·50 × 10 -⁰⁹; fi gure 2; appendix A). On the basis of sample size, our primary analysis had similar power to detect associations to disease location (ileal vs colonic) as the fi rst International Infl ammatory Bowel Disease Genetics Consortium (IIBDGC) meta-analysis on Crohn's disease. 38 However, with the exception of NOD2, MHC, and MST1, we do not report signifi cant associations between subphenotypes and individual SNPs, including those robustly associated with disease susceptibility. We noted, however, that many known risk loci showed nominal evidence for association to a range of subphenotypes, so we posited that genetic risk scores representing the combined eff ect of many individually weak signals might be a more powerful approach to study the genetic underpinnings of subphenotypes for infl ammatory bowel disease. We ¹⁸ after genome-wide signifi cant loci were removed). Risk scores that incorporated imputed HLA types that have been implicated in risk for infl ammatory bowel disease signifi cantly improved the genetic risk scores compared with those using SNPs only (appendix A).
Having shown the genetic risk score to be a useful measurement of infl ammatory bowel disease subphenotype, we used it to study the genetic relation between ileal Crohn's disease, colonic Crohn's disease, Figure 2 : Eff ect of single nucleotide polymorphisms, HLA alleles, and polygenic risk scores on phenotypes of infl ammatory bowel disease (A) Eff ect sizes for genotype-phenotype associations for risk of Crohn's disease and ulcerative colitis (odds ratio relative to controls), Crohn's disease location (odds ratio of ileal vs colonic disease), Crohn's disease behaviour (proportional odds ratio), disease extent of ulcerative colitis (odds ratio of extensive vs non-extensive disease), and age at diagnosis (linear coeffi cients) for MST1, MHC, and NOD2 variants. All eff ect sizes are per allele, and are adjusted for associations with correlated phenotypes by including them as additional predictors in the regression model, along with principal components to control for stratifi cation. See appendix A for more details on these regression models. Genome-wide signifi cant associations are depicted by fi lled circles, and error bars depict 95% CIs. (B) Eff ect sizes of genetic risk scores for disease location, disease behaviour, and age at diagnosis including all 163 susceptibility loci. Eff ect sizes are calculated by linear regression of the risk score against the phenotype, adjusted for the eff ect of the other phenotypes and for principal components, and error bars depict 95% CIs. Filled circles represent eff ects that are signifi cant after correcting for 15 phenotype-score combinations (p<0·003). Eff ect sizes are measured on scales standardised to unit variance (and thus represent the number of standard deviations that the mean phenotype increases by per standard deviation increase in the risk score). Despite the statistical signifi cance of the associations between genetic risk score and subphenotype, the small eff ect sizes translated into fairly low predictive accuracy when tested by cross-validation (appendix A). The risk score that was most signifi cantly associated with location of Crohn's disease in the primary analysis (CD vs UC) gave an area under the receiver-operating characteristic (ROC) curve of only 0·60 (95% CI 0·57-0·63) for distinguishing between colonic (L2) and ileal (L1) Crohn's disease in cross-validation, and even a specifi cally constructed ileal versus colonic score achieved an area The violin represents the range of the log CD versus UC score for the indicated subphenotype (calculated with the R package "vioplot"), with dots representing the mean of that group and error bars the 95% CIs. Although the eff ects are small compared with the variation within groups, the mean eff ects can still be measured accurately (right side of the fi gure). It can be seen on this fi gure that the Crohn's disease versus ulcerative colitis (CD vs UC) risk score placed colonic Crohn's disease between ileal Crohn's disease and ulcerative colitis. The plot also shows the positioning of the intermediate phenotypes (ileocolonic Crohn's disease and infl ammatory bowel disease unclassifi ed [IBD-U]) in between ileal and colonic Crohn's disease, and ulcerative colitis and colonic Crohn's disease, respectively. All parameters ‡ ·· ·· ·· 8·03%
*Number of risk alleles at the three NOD2 hits. †Crohn's disease versus ulcerative colitis (CD vs UC) genetic risk score (without NOD2 and MHC). ‡The total R² for these parameters, excluding the principal component used to account for population stratifi cation. In view of the correlation structure, this is not expected to be equivalent to the sum of R² obtained for each parameter. (table 5) .
To assess the possible clinical usefulness of the genetic risk score, we reassessed the cases of Crohn's disease with a low CD versus UC risk score (more ulcerative colitis-like), and cases of ulcerative colitis with a high CD versus UC risk score (more Crohn's disease-like; fi gure 4). Masked re-phenotyping of these cases raised doubts about the original diagnosis in 27% of the outlier cases compared with 8% of non-outlier cases (corrected for disease location, p=6·8 × 10 -⁴; appendix A). This fi nding suggests that we can indeed use genetics to identify small numbers of misclassifi ed patients.
Discussion
The successful identifi cation of genetic variants associated with complex diseases such as infl ammatory bowel disease has raised the exciting possibility of a more personalised approach to clinical management. In infl ammatory bowel disease, this quest is particularly urgent because of the substantial heterogeneity in disease course, and individual response to therapy. 39 Past studies in infl ammatory bowel disease have established a genetic component of disease subphenotype, 14, 16, 18, 40, 41 but these studies have been limited to a handful of candidate regions in modest numbers of patients. Our study, involving the universal application of standardised phenotyping by trained personnel on nearly 30 000 patients with infl ammatory bowel disease from 49 centres worldwide, combined with matching genotypes from more than 150 000 variants, represents the defi nitive investigation to date into the genetic basis of subphenotypes of infl ammatory bowel disease.
The only genome-wide signifi cant associations we noted were between age of onset and disease location with variants at NOD2, MHC, and 3p21. Although the associations between ileal Crohn's disease and NOD2, and those between colonic Crohn's disease and the MHC, have been previously described, [14] [15] [16] [17] [18] [19] our study has dissected the phenotype-location associations for the fi rst time. Importantly, in Crohn's disease, we showed that NOD2 is not associated with stricturing disease after accounting for disease location. These fi ndings, and the rarity of long-term change in disease location compared with behaviour, suggest that location is a fundamental biological aspect of a patient's disease, whereas behaviour (like surgery or treatment history) is a marker of disease progression. Our results for ulcerative colitis accord with the previously reported independent associations between the MHC and both extensive disease and colectomy. 17, 19 Notably, the strongest associations with extensive ulcerative colitis are variants on the ancestral 8.1 HLA haplotype. This haplotype is a known recessive risk for primary sclerosing cholangitis, 42, 43 a disease often associated with an extensive but quiescent form of ulcerative colitis. 44 Although variants associated with susceptibility to Crohn's disease and those associated with susceptibility to ulcerative colitis are both predictive of disease location, the ulcerative colitis-associated variants are the most predictive. The variants associated with disease susceptibility are also slightly predictive of age at diagnosis.
Composite genetic risk scores from all 163 independent susceptibility signals were strongly associated with all our main subphenotypes, and these fi ndings remained signifi cant after excluding NOD2 and MHC. This result accords with a similar fi nding for genetic risk scores in bipolar disorder, 45 and hints at the possibility that such approaches might be broadly applicable for studying clinical heterogeneity of common diseases. This fi nding suggests that many or most risk variants for infl ammatory bowel disease do contribute weakly to subphenotype. The relative dearth of individual single-nucleotide poly morphism associations with subphenotypes in our study, by contrast with those reported in similarly powered studies of infl ammatory bowel disease susceptibility, suggests that the genetic variants studied here have a small eff ect, and that environmental factors (such as diet, microbiota, and smoking) might be strong contributors to the subphenotypes. However, an intriguing possibility, supported by the notable absence of any functional or pathway enrichment in the components of the genetic risk scores, is that current phenotypic classifi cations do not correspond strongly to underlying molecular entities. Of particular note is the genetic distinction seen between ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis. These disease types were identifi ed as equally distinct entities on a genetic continuum: on multiple risk scores, colonic Crohn's disease was genetically intermediate between ileal Crohn's disease and ulcerative colitis, a fi nding that remained signifi cant after excluding NOD2. This result substantiates the view that colonic versus ileal disease, rather than disease extent, is the primary clinical unit of Crohn's disease classifi cation, and is further supported by the fi nding that both the genetic risk score and clinical complication rate in patients with ileocolonic disease is intermediate between that of patients with ileal disease and colonic disease. It will be of great interest, and potential clinical use, to see if application of these risk scores helps to classify the 10% of patients who are currently designated colonic infl am matory bowel disease unclassifi ed.
The composite scores were also able to identify small numbers of patients with outlier scores who were much more likely to be misdiagnosed than a typical patient. These fi ndings support the possible clinical usefulness of composite scores of multiple genetic variants, each of small eff ect. For example, genetic outliers could be excluded or specifi cally targeted for clinical trials to select more homogeneous groups. If these data were readily available, they might aff ect clinical decisions or inform risk-benefi t discussions with patients. For example, the type of surgery off ered to patients with refractory colitis crucially depends on whether they have ulcerative colitis or colonic Crohn's disease; poor outcomes (including pelvic sepsis, incontinence, and sexual dysfunction) of ileal pouch-anal anastomosis reconstruction surgery are much more common in patients with colonic Crohn's disease. Use of genetic risk scores to identify possible misdiagnoses in this group of patients could help to reduce this problem. Our data also suggest that genetic risk scores could augment biomarkers, such as faecal calprotectin, currently used for patient stratifi cation in infl ammatory bowel disease.
A limitation of our study is that the genetic variants tested were restricted to those present (and that passed quality control) on the Immunochip platform, designed for replication and fi ne mapping of potential immune-mediated disease loci. Therefore, there still might be important loci that determine disease behaviour, location, and age at onset but are independent of those that confer risk for infl ammatory bowel disease (or other immune-mediated diseases), and had limited or absent coverage on the Immunochip. A high-powered GWAS, designed to assess possibly overlooked genetic determinants for these outcomes of phenotype expressivity, which uses our large collection of cooperatively phenotyped cases of infl ammatory bowel disease with genomic DNA (and the pre-existing Immunochip genotypes), will likely be of great value. 46 In summary, our research represents the largest genotype-phenotype study in infl ammatory bowel disease done so far. Associations achieving genome-wide signifi cance were identifi ed at only three loci, suggesting that new clinical phenotypic classifi cations might need to be explored for infl ammatory bowel disease, and the relation examined between subphenotypes and other omic profi les and environmental factors, including the microbiota. 47 However, our data suggest that on the basis of genetic factors, infl ammatory bowel disease is better classifi ed into three distinct groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis), and we would recommend that clinicians adopt this nomenclature in regular practice. We also show that, although genetic risk scores do not yet have widespread clinical use, they are already valuable in some contexts in infl ammatory bowel disease, and their study in other complex disease phenotypes is warranted.
